Who Generates More Revenue? Lantheus Holdings, Inc. or Taro Pharmaceutical Industries Ltd.

Lantheus overtakes Taro in revenue after a decade-long race.

__timestampLantheus Holdings, Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 2014301600000759285000
Thursday, January 1, 2015293461000862944000
Friday, January 1, 2016301853000950751000
Sunday, January 1, 2017331378000879387000
Monday, January 1, 2018343374000661913000
Tuesday, January 1, 2019347337000669893000
Wednesday, January 1, 2020339410000644769000
Friday, January 1, 2021425208000548970000
Saturday, January 1, 2022935061000561347000
Sunday, January 1, 20231296429000572952000
Monday, January 1, 2024629182000
Loading chart...

Igniting the spark of knowledge

Revenue Race: Lantheus Holdings vs. Taro Pharmaceutical

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of success. Over the past decade, Lantheus Holdings, Inc. and Taro Pharmaceutical Industries Ltd. have been vying for dominance. From 2014 to 2023, Taro consistently outperformed Lantheus in revenue until a dramatic shift in 2022. Lantheus saw a remarkable surge, increasing its revenue by over 200% from 2014 to 2023, peaking at approximately $1.3 billion in 2023. In contrast, Taro's revenue showed a declining trend, dropping by about 25% over the same period, ending at around $573 million in 2023. This shift highlights Lantheus's strategic growth and market adaptation. However, data for 2024 is incomplete, leaving room for speculation on future trends. As these companies continue to innovate, the revenue race remains a captivating narrative in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025